Brief: Immunome Completes Acquisition Of AL102, A Phase 3 Asset For Treatment Of Desmoid Tumors
26/03/2024 12:11
March 26 (Reuters) - Immunome Inc IMNM.O :
* IMMUNOME COMPLETES ACQUISITION OF AL102, A PHASE 3 ASSET
FOR THE
TREATMENT OF DESMOID TUMORS, FROM AYALA
Source text for Eikon: ID:nBw6TbdVXa
Further company coverage: IMNM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immunome
See all newsBrief: Immunome - Enters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026
US STOCKS ON THE MOVE-Cardinal Health, nVent, Acuity
U.S. STOCKS ON THE MOVE-Cardinal Health, Fervo Energy, Rocket Lab
U.S. STOCKS ON THE MOVE-Progress Software, Vicor Corp, Accenture
Immunome climbs as Stifel initiates coverage